Payment overview · 2025
General Payments
$183.48
8 reported records · 6 companies
Healthcare provider profile · identity verified
Sumit Mahajan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · YUCCA VALLEY, CA · NPI 1659350916
Verified facts
What the public records show
CMS Open Payments records show Sumit Mahajan, MD received $183.48 in general payments during 2025 across 8 reported records.
GlaxoSmithKline, LLC. accounted for 27.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.29 | 27.9% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $41.85 | 22.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.02 | 13.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.48 | 12.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $22.50 | 12.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.34 | 11.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $183.48 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $51.29 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $41.85 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
63 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 712 | 206 |
| Lisinopril | Lisinopril | 627 | 169 |
| Amlodipine Besylate | Amlodipine Besylate | 467 | 129 |
| Meloxicam | Meloxicam | 450 | 143 |
| Levothyroxine Sodium | Levothyroxine Sodium | 425 | 105 |
| Omeprazole | Omeprazole | 417 | 113 |
| Gabapentin | Gabapentin | 391 | 112 |
| Metformin Hcl | Metformin Hcl | 362 | 111 |
| Tramadol Hcl | Tramadol Hcl | 288 | 80 |
| Trazodone Hcl | Trazodone Hcl | 279 | 76 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 265 | 84 |
| Losartan Potassium | Losartan Potassium | 265 | 77 |
| Simvastatin | Simvastatin | 244 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 240 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 225 | 57 |
| Tizanidine Hcl | Tizanidine Hcl | 224 | 79 |
| Furosemide | Furosemide | 222 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 208 | 62 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 204 | 53 |
| Eliquis | Apixaban | 184 | 37 |
| Celecoxib | Celecoxib | 168 | 73 |
| Duloxetine Hcl | Duloxetine Hcl | 168 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 162 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 159 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 154 | 35 |
| Carvedilol | Carvedilol | 151 | 43 |
| Alprazolam | Alprazolam | 150 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 140 | 33 |
| Jardiance | Empagliflozin | 137 | 29 |
| Ketoconazole | Ketoconazole | 121 | 70 |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 37 |
| Sertraline Hcl | Sertraline Hcl | 117 | 27 |
| Ozempic | Semaglutide | 116 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 113 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 110 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 108 | 32 |
| Levofloxacin | Levofloxacin | 103 | 69 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 99 | 15 |
| Potassium Chloride | Potassium Chloride | 97 | 26 |
| Montelukast Sodium | Montelukast Sodium | 96 | 28 |
| Famotidine | Famotidine | 86 | 21 |
| Bupropion Hcl Sr | Bupropion Hcl | 84 | 32 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 83 | 59 |
| Buspirone Hcl | Buspirone Hcl | 82 | 28 |
| Myrbetriq | Mirabegron | 79 | suppressed |
| Glimepiride | Glimepiride | 75 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 17 |
| Xarelto | Rivaroxaban | 73 | 15 |
| Finasteride | Finasteride | 72 | 21 |
| Januvia | Sitagliptin Phosphate | 72 | 15 |
| Allopurinol | Allopurinol | 71 | 17 |
| Atenolol | Atenolol | 70 | 17 |
| Glipizide | Glipizide | 70 | 16 |
| Azithromycin | Azithromycin | 64 | 46 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 61 | 16 |
| Levetiracetam | Levetiracetam | 60 | 12 |
| Estradiol | Estradiol | 59 | 16 |
| Lorazepam | Lorazepam | 58 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 57 | suppressed |
| Lovastatin | Lovastatin | 57 | 14 |
| Mirtazapine | Mirtazapine | 56 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 12 |
| Pregabalin | Pregabalin | 52 | 12 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 51 | 25 |
| Baclofen | Baclofen | 50 | 14 |
| Ezetimibe | Ezetimibe | 50 | 17 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 50 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 29 |
| Bupropion Xl | Bupropion Hcl | 45 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 45 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 13 |
| Fenofibrate | Fenofibrate | 43 | 13 |
| Benazepril Hcl | Benazepril Hcl | 42 | 11 |
| Clonidine Hcl | Clonidine Hcl | 42 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 12 |
| Prednisone | Prednisone | 39 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 13 |
| Meclizine Hcl | Meclizine Hcl | 37 | 15 |
| Valacyclovir | Valacyclovir Hcl | 37 | 17 |
| Ibuprofen | Ibuprofen | 35 | 20 |
| Spironolactone | Spironolactone | 35 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 33 | suppressed |
| Methocarbamol | Methocarbamol | 33 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 32 | suppressed |
| Mupirocin | Mupirocin | 30 | 20 |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Metronidazole | Metronidazole | 29 | 23 |
| Hydrocortisone | Hydrocortisone | 28 | 16 |
| Temazepam | Temazepam | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 23 |
| Clonazepam | Clonazepam | 26 | suppressed |
| Humalog | Insulin Lispro | 26 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 14 |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Invokana | Canagliflozin | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Dalfampridine Er | Dalfampridine | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 23 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 20 | suppressed |
| Cytomel | Liothyronine Sodium | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 20 | 13 |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Sulfasalazine | Sulfasalazine | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 13 |
| Latanoprost | Latanoprost | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 16 |
| Nystatin | Nystatin | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Erythromycin | Erythromycin Base | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Imiquimod | Imiquimod | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Humira Pen | Adalimumab | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Quviviq | Daridorexant Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Promethazine-Dm | Promethazine/Dextromethorphan | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $183.48 · 8 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, Dexcom G6 Transmitter, QULIPTA, TRELEGY ELLIPTA, UBRELVY, XIFAXAN, YUPELRI | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error